CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof

US9101609B2 · kind B2 · utility

Assignee

• EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC · US

Inventors

• Philip Tan · Seattle, US
• Sandy Alexander Simon · Seattle, US
• Charles G. Cerveny · Seattle, US
• Christy Anne Nilsson · Sammamish, US
• William Brady · Edmonds, US
• Jeffrey A. Ledbetter · Shoreline, US
• Martha Hayden-Ledbetter · Shoreline, US
• Peter Armstrong Thompson · Bellevue, US
• Cecile Morales · Seattle, US

Key dates

• Filing date: Apr 13, 2009
• Grant date: Aug 11, 2015
• Expiry date: Nov 28, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/50
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B-cell related autoimmune, inflammatory, or hyperproliferative diseases.